Investing at the inflection point.
Cresana invests in listed Indian equities at business inflection points — where a measurable change in fundamentals is already underway but not yet reflected in the market price. The opportunity lies in identifying that divergence early, researching it with conviction, and staying invested while it closes.
We focus on under-owned, under-researched businesses where institutional coverage is thin and sell-side attention is absent. In such businesses, a fundamental improvement tends to drive a two-stage re-rating — first as operating performance recovers, then as institutional recognition follows. Selectivity and depth of primary research are the edge, not breadth of coverage.
We do not buy any stock at any price. The entry signal must be an identifiable, measurable change already underway — capacity expansion driving operating leverage, a debt cycle completing, pricing power emerging, a business model improving, an improving commodity or pricing environment restoring margin capacity, or a previously impaired business recovering as industry dynamics shift.
We do not invest in hope. We invest in evidence of a trajectory that has already shifted.
We run 15 to 25 positions. Concentrated enough that every holding matters. Diversified enough that no single error is permanent. A concentrated portfolio built with conviction outperforms a diversified one over time — provided the research behind each position is rigorous and the entry discipline is maintained. If we cannot find 25 ideas that clear every pillar of our process, we hold fewer. Diluting the portfolio to fill a slot is not risk management — it is the opposite.
Process conviction is firm. Position conviction is conditional on the thesis remaining intact.
When the original reason for owning a position no longer holds — the thesis has broken, the catalyst has failed to materialise, or a better opportunity has emerged — we exit. The entry price is irrelevant to that decision.
We do not average down into deteriorating fundamentals. We do not chase stocks that have already fully re-rated on the thesis we identified. We do not pay up simply for the comfort of owning a well-known name.
We adapt when the evidence changes. We do not adapt when the price moves uncomfortably.